Mavyret, Maviret (pibrentasvir) is a small molecule pharmaceutical. Pibrentasvir was first approved as Mavyret on 2017-07-26. It is used to treat hepatitis c in the USA. It has been approved in Europe to treat chronic hepatitis c. Mavyret's patents are valid until 2035-06-05 (FDA).
|Indication||chronic hepatitis c, hepatitis c|
|Drug Class||Antivirals: NS5A inhibitors|